BioSpace News Archive

Replimune Group, Inc. today announced that the Company has entered into a Master Clinical Trial Collaboration and Supply Agreement in relation to Replimune’s RP2/3 program in colorectal cancer (CRC) and hepatocellular carcinoma (HCC).

Castellum, Inc. announced today that Mark C. Fuller, Chief Executive Officer, David T. Bell, Chief Financial Officer, and Jay O. Wright, Chief Legal Counsel of the Company, as well as several independent directors of CTM, have recently made open market purchases of Castellum common stock.

HAPPE Spine announces that Andrew Iott has accepted an offer to become the President and CEO.

Atsena Therapeutics today announced that Patrick Ritschel, Chief Executive Officer, will present a company overview at the Emerging Life Science Company Showcase hosted by NewYorkBIO and NYSE.

1health.io Inc. (“1health”), an industry-leading software company that empowers laboratories to launch new test products quickly into both clinical and online markets, partners with Dante Genomics to help launch their whole genome sequencing test to their customers in the United States with online prescription services.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic diseases, today announced new preclinical data supporting the progression of PGN-EDODM1, PepGen’s product candidate in development for the treatment of myotonic dystrophy type 1 (DM1), into clinical trials.

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today issued a letter to shareholders.

Cerevance today announced that Craig Thompson, chief executive officer of Cerevance, will present at the upcoming RBC Capital Markets Virtual Healthcare Private Company Conference being held virtually December 14-15, 2022.

Ocugen, Inc. today announced that the Data Safety and Monitoring Board (DSMB) for the OCU400 clinical trial recently convened and established high dose as the maximum tolerable dose (MTD) in the dose-escalation phase of the study.

Pimera Therapeutics, Inc., a clinical-stage biotechnology company focused on developing breakthrough medicines for cancer and other diseases with high unmet medical need, announced today that Pimera’s President and CEO, Mustapha Haddach, Ph.D., will present a corporate overview at the Biotech Showcase 2023 meeting on Monday, January 9, 2023, at 5:15 PM.